Biogen Inc. (BIIB)
| Previous close | 193.18 |
| Open | 199.18 |
| Bid | 192.14 x 100 |
| Ask | 212.93 x 100 |
| Day's range | 198.97 - 205.72 |
| 52-week range | 189.44 - 319.76 |
| Volume | |
| Avg. volume | 1,201,566 |
| Market cap | 29.873B |
| Beta (5Y monthly) | -0.01 |
| PE ratio (TTM) | 25.75 |
| EPS (TTM) | 7.98 |
| Earnings date | 24 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 297.80 |
Barrons.comBiogen Stock Rises After Earnings and on Jump in Alzheimer’s Drug Sales
Biogen says first-quarter global in-market sales of Leqembi were about $19 million, nearly triple the fourth quarter of 2023.
- GuruFocus.com
Biogen Inc (BIIB) Q1 2024 Earnings: Mixed Results Amidst Strategic Growth Efforts
Despite Revenue Decline, Non-GAAP EPS Growth and Strategic Initiatives Show Promise
ReutersBiogen cost cuts drive profit beat, Alzheimer's drug sales jump
(Reuters) -Biogen beat market estimates for first-quarter profit on Wednesday as a series of cost-cutting measures helped offset the impact of fierce competition for its older drugs, sending its shares up nearly 7% before the bell. The launch has led to profound changes in how doctors treat Alzheimer's patients, and challenges include the "amount of effort it takes to actually be able to initiate even the first patient", CEO Christopher Viehbacher said in an interview. The number of patients on Leqembi have increased nearly 2.5 times from roughly 2,000 patients at the end of 2023, Biogen said.
